Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
Clarient Launches New Gene Mutation Test for Lung Cancer
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
